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Abstract
The oncogenic Epstein Barr virus (EBV) infects the majority of the human population and
usually persists within its host for life without symptoms. The EBV oncoproteins nuclear anti-
gen 3A (EBNA3A) and 3C (EBNA3C) are required for B cell transformation in vitro and are
expressed in EBV associated immunoblastic lymphomas in vivo. In order to address the
necessity of EBNA3A and EBNA3C for persistent EBV infection in vivo, we infected NOD-
scid γcnull mice with reconstituted human immune system components (huNSG mice) with
recombinant EBV mutants devoid of EBNA3A or EBNA3C expression. These EBV mutants
established latent infection in secondary lymphoid organs of infected huNSG mice for at
least 3 months, but did not cause tumor formation. Low level viral persistence in the absence
of EBNA3A or EBNA3C seemed to be supported primarily by proliferation with the expres-
sion of early latent EBV gene products transitioning into absent viral protein expression with-
out elevated lytic replication. In vitro, EBNA3A and EBNA3C deficient EBV infected B cells
could be rescued from apoptosis through CD40 stimulation, mimicking T cell help in second-
ary lymphoid tissues. Thus, even in the absence of the oncogenes EBNA3A and 3C, EBV
can access a latent gene expression pattern that is reminiscent of EBV persistence in
healthy virus carriers without prior expression of its whole growth transforming program.
Author summary
Epstein Barr virus (EBV) was discovered 54 years ago as the first human candidate tumor
virus. In vitro, EBV can readily transform human B cells into indefinitely growing cell
lines. In this transformation process, multiple EBV proteins play an important role, such
as the two oncogenes EBNA3A and especially EBNA3C. To address the necessity of these
oncogenes in vivo, we investigated EBNA3A and 3C deficient EBV for their persistence in
mice with reconstituted human immune system components (huNSG mice), an in vivo
model for EBV infection, associated tumorigenesis and immune control. Here, we show
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that EBV devoid of EBNA3A or EBNA3C was able to establish latent infection in vivo.
The persistence was characterized through proliferation with the expression of early latent
EBV gene products transitioning into absent viral protein expression, but without tumor
formation. Furthermore, we were able to rescue in vitro infected B cells with EBNA3A or
EBNA3C deficient EBV from apoptosis by mimicking T cell help. This might allow the
virus to access the gene expression pattern that is thought to also mediate persistence in
healthy EBV carriers and does not seem to require prior expression of all growth trans-
forming viral proteins.
Introduction
Epstein Barr virus (EBV) was discovered as the first human candidate tumor virus in Burkitt
lymphoma 54 years ago [1, 2]. EBV is probably the most potent of all the human tumor viruses,
because it can readily transform human B cells in vitro [3]. In the resulting lymphoblastoid cell
lines (LCLs) all nine latent EBV proteins and non-translated RNAs are expressed [4]. These
include the six nuclear antigens (EBNA1, 2, LP, 3A-C) and the three latent membrane proteins
(LMP1, 2A and 2B). This so-called latency III program can also be found in naïve B cells of
healthy virus carriers and lymphoproliferations that emerge in immune compromised individ-
uals, like post-transplant lymphoproliferative disorder (PTLD) and immunoblastic lymphoma
[5]. In germinal center B cells and latency II associated malignancies, like classical Hodgkin
lymphoma, only the EBNA1, LMP1 and LMP2 proteins are present [4, 5]. Latency I is charac-
terized by the sole expression of EBNA1 and this viral expression pattern can be found in Bur-
kitt lymphomas and EBV infected homeostatically proliferating memory B cells [6]. Finally,
EBV persists in non-replicating memory B cells without viral protein expression and reacti-
vates upon plasma cell differentiation to produce infectious viral particles at mucosal surfaces
for transmission [7, 8]. These previously published studies suggested that EBV persistence can
only be achieved upon further differentiation of latency III infected naïve B cells through
latency II and I towards memory B cells in which the virus can reside undetectable to the
immune system.
Accordingly, EBV latency III establishment during primary B cell infection in vitro and the
resulting outgrowth of LCLs were taken as surrogates for EBV persistence. Upon B cell infec-
tion by EBV, the transient expression of the two viral Bcl-2 homologues BHRF1 and BALF1
initially ensures the survival of EBV harboring cells [9]. During the first two days, proliferation
of the infected cells is initiated by EBNA2, probably with the help of EBNA-LP, via expression
of cell cycle genes including c-myc, cyclin D2 and E [10]. The resulting DNA damage response
and BIM as well as p16INK4a up-regulation is blocked primarily by EBNA3C with the help of
EBNA3A [10–13]. Therefore, latency III expressing lymphoblastoid cell lines cannot be estab-
lished with EBV deficient in EBNA3C and only with great difficulties from EBNA3A knock-
out viruses [14, 15]. Two weeks after initial infection LMP1, 2A and 2B expression will start to
contribute to the proliferation of EBV infected B cells via LMP1-dependent NF-κB activation,
mimicking CD40 signaling, and LMP2A and 2B’s survival-inducing B cell receptor-like signal-
ing [16, 17]. In order for the latency III transcription program not to kill the host due to
uncontrolled B cell proliferation, EBNA3B allows for the increased expression of chemokines
that attract T cells, which then in turn restrict latency III transformed B cells by their cytotoxic
function and promote the switch from latency III to II by repressing EBNA2 via germinal cen-
ter associated cytokines [18–21]. These studies postulated that EBNA3C is essential for latency
III establishment and that B cell transformation is essential for EBV persistence in vivo.
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Therefore, we investigated EBNA3A and EBNA3C deficient EBV viruses for their persis-
tence in mice with reconstituted human immune system components (huNSG mice), an in
vivo model for persistent EBV infection, EBV associated lymphomagenesis and cell-mediated
immune control of EBV [22]. Surprisingly, we found that both EBNA3A and EBNA3C defi-
cient EBVs were able to persist in huNSG mice, albeit at a lower level compared to wildtype
infection. The presence of the mutant viruses could mainly be detected in secondary lymphoid
tissues without lymphomagenesis after four to twelve weeks of infection. The persistence was
characterized by EBER and EBNA2 expression accompanied by very low LMP1 expression,
which transited into EBER only expression after three months. Especially EBNA3C deficient
EBV showed markedly reduced or even absent LMP1 expression. Supplementation of CD40
signaling rescued EBNA3C deficient EBV infected B cells in vitro. Thus, we suggest that EBV
can persist without EBNA3A or EBNA3C expression in vivo, utilizing signals from the micro-
environment of secondary lymphoid tissues, including CD40 stimulation by CD40L. With this
microenvironmental help EBV seems to be able to access latency 0 after EBNA2 driven prolif-
eration without ever expressing all proteins associated with the latency III program. This sug-
gests that latency III and 0 are not consecutive EBV gene expression programs, but alternative
pathways after EBNA2 driven proliferation.
Results
EBV persists without EBNA3A or EBNA3C in vivo
EBNA3A knock-out EBV (3AKO) and EBNA3C knock-out EBV (3CKO) were previously
shown to be unable to establish indefinitely growing LCLs in vitro [14], and only few EBNA3A
deficient LCLs were derived with significant difficulties [15]. Until now, the importance of
EBNA3A and EBNA3C for EBV persistence in vivo has not been investigated. Our group
among others could previously demonstrate that NOD-scid γcnull mice with reconstituted
human immune system compartments (huNSG mice) are suitable models to study persistent
EBV infection and immune control in vivo [23, 24]. In order to identify the role of EBNA3A
or EBNA3C during EBV infection in vivo we inoculated huNSG mice with 105 Raji-infectious
units (RIU) of 3AKO, 3CKO or wildtype EBV (wt). EBV DNA was readily detected in the
spleen and lymph nodes of the majority of both 3AKO and 3CKO infected mice 5 weeks p.i.
(Fig 1A and 1B). The viral DNA burden, however, was significantly lower compared to that of
wt infected animals (Fig 1A and 1B). In order to detect persistent EBV infection in the absence
of EBNA3A and EBNA3C more clearly, huNSG mice were infected with a higher inoculation
dose of 106 RIU in subsequent experiments. Wt infection with 106 RIU results in rapid weight
loss and death of the infected animals and was thus not performed. The resulting viral DNA
loads in the spleen and lymph nodes were slightly higher compared to the 105 RIU infections
and remained similar between the two KO virus infected groups (Fig 1A and 1B). However,
despite infection with the higher infectious dose, viral DNA in the blood of 3AKO or 3CKO
infected animals could still only rarely be detected at very low levels (Fig 1C). Hence, persis-
tence of 3AKO or 3CKO viruses was mainly found in secondary lymphoid organs of infected
animals (Fig 1D). Active EBV transcription demonstrated by EBER in situ hybridization in
splenic sections from 3AKO and 3CKO infected animals confirmed viral persistence (Fig 1E).
The number of EBER+ cells/mm2 in the spleen was similar in 3AKO and 3CKO, but reduced
compared to wt infected mice (Fig 1F). EBER+ cells could be found up to 3 months of infection
(Fig 1G and 1H) and likewise, EBV DNA was still detected in spleen and lymph nodes of
3AKO or 3CKO infected mice 3 months p.i. (Fig 1I). EBV infected cells, illustrated by EBNA2
staining or EBER in situ hybridization, were mostly CD20+ and CD3- indicating viral presence
in B cells in all experimental groups (S1 Fig). Despite persistent low-level infection, neither
EBV persistence without EBNA3A and 3C
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3AKO nor 3CKO inoculation resulted in tumor formation in huNSG mice. Hence, in contrast
to previously published in vitro data [14], EBNA3A and EBNA3C seem to be dispensable for
persistent EBV infection in vivo.
EBNA3A and EBNA3C deficient EBV infection causes CD8+ T cell
expansion
Wildtype infection in huNSG mice has been shown to induce the expansion of human CD8+ T
cells and result in splenomegaly [24]. As a second readout for EBV persistence in the absence
of EBNA3A or EBNA3C, we investigated the cellular immune response in huNSG mice against
3AKO or 3CKO infection. The number of splenic (Fig 2A) and blood (S2A Fig) CD8+ T cells
was significantly increased in 105 RIU of 3CKO infected animals 5 weeks p.i. compared to
uninfected animals. In low dose (105 RIU) 3AKO infected mice a similar trend for an increase
of splenic CD8+ T cells was observed (Fig 2A). However, both 3AKO and 3CKO infected mice
had significantly lower numbers of splenic and blood CD8+ T cells compared to wt infected
mice (Fig 2A and S2A Fig). High dose (106 RIU) infection with 3AKO and 3CKO resulted in a
significantly higher number of splenic CD8+ T cells in both groups compared to the uninfected
group (Fig 2A) and similar trends were observed in the blood (S2A Fig). In parallel CD8+ T
cell activation, as assessed by HLA-DR up-regulation, was observed in spleen and blood after
wt and knock-out virus infections (S3A, 3B, 3C and 3D Fig). However, in contrast to CD8+ T
cells, the number of splenic and blood CD4+ T cells did not differ significantly in the different
experimental groups irrespective of viral dose, except for a significant splenic CD4+ T cell
accumulation after 105 RIU 3CKO infection and significant HLA-DR up-regulation on spleen
and blood CD4+ T cells after wt infection and a trend in HLA-DR up-regulation for 3AKO
and 3CKO infection (Fig 2B and S2B, S3E, S3F, S3G and S3H Figs). Furthermore, splenomeg-
aly, characteristic for wt infection, was not observed in 3AKO or 3CKO infected mice with the
lower infectious dose (Fig 2C). High dose infection with 3AKO led to significant splenomegaly
compared to uninfected mice, whereas 3CKO infected mice only showed a trend towards
splenomegaly (Fig 2C). Interestingly, 3AKO or 3CKO high dose infected mice had a clear
increase in CD8+ T cells in the spleen, but to a lesser extent in the blood. These findings mirror
the prevalence of 3AKO or 3CKO infected cells in secondary lymphoid tissues and indicate
that cellular immune responses against 3AKO and 3CKO are mounted in huNSG mice.
EBNA3A and EBNA3C deficient EBV persists without elevated lytic
replication
Next, we investigated whether EBV entered into lytic replication as a means for persistence
without EBNA3A or EBNA3C. BZLF1 is the first gene expressed in the lytic cycle of EBV and
Fig 1. EBV persists without EBNA3A or EBNA3C in vivo. (A) Splenic endpoint viral DNA load and (B) viral DNA load per gram lymph node tissue determined by
qPCR of huNSG mice infected with either 105 RIU of wt, 3AKO or 3CKO for 5 weeks (spleen: n = 18-21/group, lymph node: n = 8-11/group) or 106 RIU of 3AKO or
3CKO for 6 weeks (spleen: n = 13-14/group, lymph node: n = 12-13/group). Values for mice in which no viral DNA was detected are plotted on the X-axis. (C) Blood
DNA viral load over time determined by qPCR of huNSG mice infected with either 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. (n = 18-21/group) or 106 RIU of 3AKO
or 3CKO 6 weeks p.i. (n = 13-14/group). Horizontal dashed line indicates the viral load of 3 times the lower limit of quantification (LLOQ). Horizontal dotted line
indicates the LLOQ. (D) Frequency of huNSG mice infected with 105 RIU of 3AKO, 3CKO or wt 5 weeks p.i. or 106 RIU of 3AKO or 3CKO 6 weeks p.i. with EBV
DNA copies above (200) or below (<200) 3 times the LLOQ in either the blood, the spleen or lymph nodes (n = 10-13/group) as determined by qPCR. Pooled data
from 4 low and 2 high infectious dose experiments. P< 0.05, P< 0.01, Fisher’s exact test. (E) EBER-ISH (original magnification, 400x) of splenic sections from
huNSG mice infected with 106 RIU of 3AKO or 3CKO 6 weeks p.i.. (G) EBER-ISH (original magnification, 200x) of splenic sections from huNSG mice infected with
105 RIU of 3AKO or 3CKO 12 weeks p.i.. (F, H) Quantification of EBER+ cells/mm2 of E (n = 10-13/group) and G (n = 3-5/group) respectively and of huNSG mice
infected with 105 RIU of wt 5 weeks p.i. (n = 4/group) or mock (n = 3-8/group). (I) Frequency of huNSG mice infected with 105 RIU of 3AKO or 3CKO 12 weeks p.i.,
with EBV DNA copies above (200) or below (<200) 3 times the LLOQ in either the blood, the spleen or lymph nodes (n = 3-5/group) as determined by qPCR. Pooled
data from 2 experiments. (A-C) Pooled data from 4 low and 2 high infectious dose experiments are displayed with mean ± SEM. P< 0.01, P< 0.001, two-way
ANOVA with Bonferroni correction for blood viral load and Mann-Whitney U test for splenic viral load, lymph node viral load and EBER-ISH.
https://doi.org/10.1371/journal.ppat.1007039.g001
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transactivates viral replication [25, 26], which was shown in vivo to occur in plasma cells of healthy
EBV carriers [8]. Therefore, both BZLF1 expression as well as plasma cell presence was determined.
The number of BZLF1+ cells and CD138+ plasma cells in splenic sections of 3AKO or 3CKO
infected huNSG mice was determined by immunohistochemistry (Fig 3A and S4A and S4C Fig).
BZLF1+ cells seemed to be absent in spleen sections of 3AKO or 3CKO infected animals, presum-
ably due to low viral loads, since also in wt infected mice just a few BZLF1+ cells were present (Fig
3A and 3B, S4C Fig). Furthermore, we did not detect a significant difference in the number of
plasma cells in mice infected with 3AKO or 3CKO at 106 RIU compared to uninfected mice (S4A
and S4B Fig). To assess lytic activity further, we measured viral DNA presence in the serum, which
has previously been proposed to be correlated with the lytic phase of infection [27]. DNA viral
loads seemed to be virtually absent in the serum of 3AKO and 3CKO infected animals irrespective
of EBV dose, whereas in wt infected animals, DNA viral loads were observed (Fig 3C and 3D).
Hence, lytic replication was mainly found in wt, but not in KO infected animals (Fig 3B and 3D).
In line with these findings, we found significantly lower BZLF1mRNA expression in 3CKO
infected B cells compared to wt infected B cells in vitro. Furthermore, there was no difference in the
expression of BZLF1 in 3AKO in comparison to wt infected B cells (S5 Fig). Together, 3AKO and
3CKO seem not to persist due to an increase in lytic replication in secondary lymphoid organs.
EBV infected cells proliferate without EBNA3A or EBNA3C in vivo
In vitro 3CKO infected B cells were shown to proliferate for up to 30 days prior to eventual
arrest or cell death [12, 28]. Nevertheless, the remaining living cells contain viral DNA. To
Fig 2. EBNA3A or EBNA3C deficient EBV infection causes CD8+ T cell expansion. (A) The number of splenic CD8+ T cells and (B) splenic CD4+ T cells of huNSG
mice infected with either 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. (n = 14-21/group) or 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 7-13/group) or non-infected
control (mock) huNSG mice was determined by flow cytometry, applying the determined frequency to the spleen cell count. (C) The ratio of spleen to body weight
(BW) of individual huNSG mice infected with either 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. (n = 14-21/group) or 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 7-13/
group) or non-infected control (mock) huNSG mice is depicted. (A-C) Pooled data from 4 low and 2 high infectious dose experiments with mean ± SEM. P< 0.05,
P< 0.01, P< 0.001, Mann-Whitney U test.
https://doi.org/10.1371/journal.ppat.1007039.g002
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investigate if the observed viral load in 3AKO or 3CKO infected mice 5 to 6 weeks p.i. was due
to arrested non-proliferating B cells, we performed immunofluorescence co-stainings for
EBNA2 and Ki67 of splenic sections from wt, 3AKO and 3CKO infected mice. EBNA2 positive
cells were detected in most of the infected mice, but not in uninfected animals, whereas Ki67
positive cells were detected in all groups (Fig 4A). Cells double-positive for EBNA2 and Ki67
were detected in wt, as well as KO infected groups (Fig 4A). The frequency of Ki67 expressing
cells of EBNA2 positive cells was comparable between wt and KO infected mice (Fig 4B). These
findings reveal the proliferation of EBV infected cells in KO infected mice for up to 6 weeks.
EBNA3A and EBNA3C deficient EBV persist without viral protein
expression
Since lytic replication was not likely responsible for 3AKO and 3CKO persistence, we aimed
to investigate the role of latent genes during infection with these viruses in vivo. Specifically,
we explored three important proteins for B cell transformation upon EBV infection, the early
transactivator EBNA2 and the later expressed LMP1 and LMP2A [10, 16]. In splenic B cells
derived from huNSG mice infected with 3AKO or 3CKO, EBNA2 mRNA expression was
similar to wt LCLs cultured in vitro (Fig 5A). However, LMP1 and LMP2A expression was signif-
icantly lower in both 3AKO and 3CKO infected animals compared to LCLs (Fig 5A). Further-
more, EBNA2+ cells were also detected by immunohistochemistry in splenic sections from
3AKO and 3CKO infected mice (Fig 5B and 5C), whereas LMP1 protein expression was virtually
absent after inoculation with 105 (Fig 5B) or 106 RIU (Fig 5C). In line with the quantification of
Fig 3. EBNA3A and EBNA3C deficient EBV persist without elevated lytic replication. (A) Representative immunohistochemistry staining for BZLF1 (original
magnification, 400x) in splenic sections of huNSG mice infected with 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i.. (B) Frequency of huNSG mice infected with 105 RIU
of 3AKO, 3CKO or wt 5 weeks p.i. with BZLF1+ or BZLF1- cells in splenic sections as determined by immunohistochemistry. (C) DNA EBV genome copies determined
by qPCR in serum of animals infected with either 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. (n = 15-20/group) or 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 11-14/
group). Values for mice in which no viral DNA was detected in the serum are plotted on the X-axis. Horizontal dotted line indicates the LLOQ. Pooled data from 4 low
and 2 high infectious dose experiments represented with the mean ± SEM. P< 0.001, Mann-Whitney U test. (D) Frequency of huNSG mice infected with 105 RIU of
3AKO, 3CKO or wt 5 weeks p.i. with EBV DNA copies above (67) or below (<67) the LLOQ in the serum (n = 15-20/group) as determined by qPCR. (B, D) Pooled
data from 4 experiments. P< 0.001, P< 0.005, Fisher’s exact test.
https://doi.org/10.1371/journal.ppat.1007039.g003
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viral DNA in the spleen, there were significantly fewer EBNA2 and barely detectable LMP1
expressing cells in mice infected with 3AKO or 3CKO in comparison to mice infected with wt
virus (Fig 5D and 5E). Interestingly, EBNA2 expression decreased with time from 5–6 weeks to
12 weeks of persistent infection with 3AKO or 3CKO (Fig 5D, red bars), while LMP1 expression
remained low to almost non-detectable (Fig 5E, red bars). A single 3CKO infected mouse
showed EBNA2 and LMP1 protein expression which was comparable to wt infection at 12
weeks after infection (Fig 5D and 5E, red square and Fig 5G). Therefore, in the majority of cases
it seems that EBV lacking EBNA3A or EBNA3C persists with EBNA2 expression, but dramati-
cally reduced or absent LMP1 and LMP2A expression, and seems to transit to latency 0/I after
three months of EBV infection. To better characterize the latency stage at 12 weeks after infec-
tion, we determined EBNA1 protein expression by immunohistochemistry (Fig 5F and 5G).
Whereas no EBNA1+ cells were detected in the majority of splenic sections (Fig 5F), the one
3CKO infected mouse showing EBNA2 and LMP1 expression also showed clear EBNA1 expres-
sion (Fig 5G). Therefore, 3AKO or 3CKO infection transits into latency 0 at 12 weeks after infec-
tion, but transition into a growth transforming latency program rarely occurs. Since only a
subset of splenic B cells is infected with the recombinant 3AKO or 3CKO viruses, but the
EBNA2 transcription levels are similar to homogenously EBV transformed LCLs, EBNA2 tran-
scription seems to even be elevated, possibly as a compensatory mechanism for the diminished
expression of LMP1 and 2. Nevertheless, this primarily EBNA2 driven proliferation allowed for
the transition into mostly latency 0 after three months of infection.
CD40 stimulation rescues EBNA3A and EBNA3C deficient EBV infected B
cells in vitro
Previous work has suggested that in the absence of LMP1 EBV can persist through CD40 stim-
ulation provided from the microenvironment [28]. To address the role of CD40 stimulation in
EBV lacking EBNA3A or EBNA3C, we infected CD19+ B cells, purified from human leucocyte
concentrates with wt, 3AKO or 3CKO viruses in the presence of fibroblasts either expressing
Fig 4. EBV infected cells proliferate without EBNA3A or EBNA3C in vivo. (A) Representative immunofluorescence staining for
EBNA2 (red), Ki67 (green) and DAPI (blue) (original magnification, 200x) in splenic sections of huNSG mice infected with wt, 3AKO
or 3CKO 5 or 6 weeks p.i.. (B) Quantification of A with the frequency of Ki67+ EBNA2+ cells of all EBNA2+ cells (n = 4-15/group).
Pooled data from 2 experiments with mean ± SEM, Mann-Whitney U test.
https://doi.org/10.1371/journal.ppat.1007039.g004
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CD40L [29] or not. The frequency of living infected cells (EBV encoded GFP+) in the presence
of CD40L (as inferred from the difference in culture conditions with or without CD40L) was
significantly higher in 3CKO infected B cells 2 and 3 weeks p.i. as well as in 3AKO infected B
cells 3 weeks p.i. compared to wt infected B cells (Fig 6A and 6B). Consistent with these find-
ings, the frequency of Annexin V+ 7AAD- early apoptotic cells in the absence of CD40L (as
inferred from the difference in culture conditions with or without CD40L) were significantly
increased after 3, but not 2 weeks in 3CKO infected cultures compared to wt infected cultures
(Fig 6C and 6D). This data indicates that CD40 stimulation can markedly contribute to the
persistence of 3AKO and 3CKO infected B cells and might be provided by the microenviron-
ment for EBV persistence in the absence of EBNA3A and EBNA3C in vivo.
Fig 5. EBNA3A and EBNA3C deficient EBV persist without viral protein expression. (A) Relative EBNA2, LMP1 and LMP2AmRNA expression
normalized to GAPDH in purified splenic B cells from huNSG mice infected with 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 9-12/group) and LCL
from 4 different donors. The horizontal dashed lines indicate the detection limits of the RT-qPCR assays. Values for mice in which no LMP1 transcripts
were detected are plotted on the X-axis. (B, C, G) Staining for EBNA2 ((B, C) upper column, original magnification, 200x) or LMP1 ((B, C), lower
column, original magnification, 200x) and (D, E) the quantification of EBNA2+ or LMP1+ cells/mm2 in splenic section of huNSG mice infected with
either (B, D, E) 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. (n = 17-20/group) indicated by black bars, (D, E, G) 105 RIU of 3AKO or 3CKO 12 weeks p.i.
(n = 3-5/group) indicated by red bars/square or (C-E) 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 11-13/group) or non-infected control (mock) huNSG
mice. (F, G) Staining for EBNA1 (original magnification, 200x) in splenic sections of huNSG mice infected with 3AKO or 3CKO 12 weeks p.i. or non-
infected control (mock) huNSG mice. (A, D, E) Pooled data from 4 and 2 experiments represented with the mean ± SEM, P< 0.01, P< 0.001,
Mann-Whitney U test.
https://doi.org/10.1371/journal.ppat.1007039.g005
Fig 6. CD40 stimulation rescues EBNA3A and EBNA3C deficient EBV infected cells in vitro. Purified human B cells were
infected with wt, 3AKO or 3CKO and cultured with irradiated fibroblasts either expressing CD40L or not (n = 6). (A, B) The
change in the frequency of living infected cells (GFP+) cells between the culture condition with CD40L or without CD40L for
wt, 3AKO or 3CKO infected B cells (A) 2 and (B) 3 weeks p.i., determined with 7AAD life-dead stain by flow cytometry. (C, D)
The change in the frequency of early apoptotic Annexin V+ 7AAD- cells between the culture condition with CD40L or without
CD40L for wt, 3AKO or 3CKO infected B cells (C) 2 and (D) 3 weeks p.i., determined by flow cytometry. (A-D) Pooled data
from 3 experiments represented with the mean ± SEM, P< 0.05, P< 0.01, P< 0.001, paired t-test.
https://doi.org/10.1371/journal.ppat.1007039.g006
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In order to assess the role of CD4+ T cells in providing a CD40 stimulating microenviron-
ment as well as in exerting immune control in vivo, we depleted these cells with a CD4 specific
antibody during 3AKO and 3CKO infection (S6 Fig). We observed elevated viral loads for
3AKO infection in spleen, lymph nodes and blood, while 3CKO viral loads were unchanged.
This suggests that during EBV infection in the absence of EBNA3A, immune control by CD4+
T cells dominated over any supportive role of helper T cells, while these nurturing and
immune control functions might have balanced each other during 3CKO infection and
thereby viral loads were not altered upon CD4 depletion. Together, these data indicate that
3AKO and in particular 3CKO infection might benefit from CD40 stimulation for persistence.
Elevated p16INK4a expression in EBV infected cells without EBNA3A or 3C
in vivo
In order to determine if such a microenvironment support might be associated with cell cycle
regulation in vivo, we monitored the p16INK4a expression levels in EBNA2 positive cells in
splenic sections of 3AKO or 3CKO infected mice 5 to 6 weeks p.i. by immunofluorescence
(Fig 7). p16INK4a and BIM expression levels had previously been reported to be suppressed by
EBNA3A and 3C, thereby supporting proliferation and inhibiting cell death of EBV infected
cells in vitro [10–13]. In contrast to wt infection most 3AKO and 3CKO infected cells
expressed p16INK4a (Fig 7B). Thus, absence of EBNA3A or 3C indeed elevates p16INK4a levels
in EBNA2 positive cells and presumably increases apoptosis risk of EBV infected B cells also in
vivo. We propose that elevated p16INK4a levels hinders efficient viral amplification and estab-
lishment of full latency III diverting infected cells into latency 0 for persistence. This further
suggests that up-regulation of p16INK4a in 3AKO and 3CKO infection might contribute to the
lack of tumor formation that is observed in vivo.
Discussion
Contrary to previous in vitro studies that require B cell transformation to maintain infected
cells [14], we demonstrate that EBV infection can persist in the absence of EBNA3A or
EBNA3C for at least 3 months in vivo. Persistence is mainly restricted to secondary lymphoid
tissues and is characterized by initial EBNA2 expression with diminished LMP1 as well as
LMP2A presence and lytic replication, while viral DNA in peripheral blood remains mostly
undetectable. After 3 months solely EBER expression without expression of EBNA1, EBNA2
or LMP1 can be detected in EBV infected splenocytes. Since EBV infected B cells can be sus-
tained in vitro in the absence of EBNA3A and EBNA3C by CD40L mediated CD40 engage-
ment, we suggest that the microenvironment of secondary lymphoid tissues, possibly via
CD40L on CD4+ T cells, allows for the persistence of EBNA3A and EBNA3C deficient EBV
after infection. With this microenvironmental help and without the need to enter into com-
plete latency III, EBV infected B cells seem to be able to access a viral gene expression program
that is associated with long-term persistence in healthy EBV carriers and characterized by
absence of viral protein expression and presence of non-translated viral RNAs like EBERs.
Indeed, absence of LMP1, which might directly result from loss of LMP1 promotor activa-
tion by EBNA3C [30–33] and constitutively engages the CD40 signaling machinery [34], has
been previously reported to still allow EBV persistence in huNSG mice, even so no B cell trans-
formation can be achieved with LMP1 deficient EBV in vitro [28]. The authors demonstrated
that CD4+ T cells contributed via CD40L mediated CD40 stimulation to persistence and lym-
phomagenesis of LMP1 deficient EBV in vivo. Accordingly, T cells heavily infiltrated the
respective EBNA2 positive tumors, which also expressed the EBNA2 driven c-myc oncogene.
Therefore, the microenvironment in secondary lymphoid tissues can supplement signals that
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are essential for B cell transformation and persistence by EBV. We now demonstrate for an
even earlier check-point in B cell transformation, EBNA3A or EBNA3C, which rescues B cells
that are driven into proliferation by EBNA2 expression [10–12], that the microenvironment of
secondary lymphoid tissues in huNSG mice allows EBV persistence in the absence of EBNA3A
or EBNA3C expression. These findings argue that latency 0, which is considered to form the
basis of EBV persistence in memory B cells of healthy virus carriers, can develop from an
EBNA2 driven proliferation program without expression of EBNA3A, EBNA3C, LMP1 and
LMP2A. Thus, latency III and 0 might represent two alternative pathways of infection originat-
ing from early latent EBV protein expression (Fig 7C).
Indeed, EBV persists in memory B cells at a frequency of 1 in 104 to 105 in the peripheral
blood of healthy virus carriers without the expression of EBNA3A, EBNA3B, LMP1 and
LMP2A [5, 7]. This cellular compartment of EBV infected memory B cells expands during
symptomatic primary EBV infection, called infectious mononucleosis (IM), resulting in up to
50% being EBV positive [35]. Two pathways have been suggested to seed this peripheral mem-
ory B cell compartment with EBV infected cells. In tonsils of healthy virus carriers naïve B cell
infection might lead to latency III and force the respective cells into the germinal center reac-
tion [5]. Cytokines in the germinal center reaction, secreted by follicular helper T cells, might
Fig 7. Elevated p16INK4a expression in EBV infected cells without EBNA3A or 3C in vivo. (A) Representative immunofluorescence staining for EBNA2 (red),
p16INK4a (green) and DAPI (blue) (original magnification, 200x) in splenic sections of huNSG mice infected with wt, 3AKO or 3CKO 5 or 6 weeks p.i.. (B)
Quantification of A with the frequency of p16INK4a+ EBNA2+ cells of all EBNA2+ cells (n = 3-5/group). Pooled data from 2 experiments with mean ± SEM, unpaired
t-test with Welch’s correction. (C) Schematic representation of B cell infection by EBV in humanized mice.
https://doi.org/10.1371/journal.ppat.1007039.g007
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even be required to exit latency III and down-modulate EBNA3A and 3C expression [19].
Finally, late latent EBV gene expression like LMP1 and LMP2A might rescue EBV infected
centroblasts and centrocytes into the memory B cell compartment by mimicking B cell recep-
tor and T cell help signaling [5]. In contrast, germinal centers are largely dissolved in IM ton-
sils [36]. Under these circumstances independent of a germinal center reaction, direct
infection of memory B cells might seed this persistent lymphocyte compartment with EBV
without the need of LMP1 and LMP2A expression [36]. Similarly in our huNSG mice, germi-
nal center development is rudimentary [37, 38], and EBNA3A or 3C deficient EBV in this
study gained access to persistence in latency 0 without significant LMP1 and LMP2A expres-
sion. These considerations suggest that B cell transformation, which is only achieved on very
rare occasions by EBNA3A and 3C deficient EBV viruses, is not necessary to develop the
latency 0 program of long-term persistence in memory B cells and a direct differentiation
from EBNA2 induced proliferation into persistence without viral protein expression can be
achieved, bypassing the germinal center reaction.
Materials and methods
Recombinant EBV
Epstein-Barr-virus B95.8 (EBV) was produced from EBNA3A knock-out (3AKO), EBNA3C
knock-out (3CKO) or wildtype (wt) BACs maintained in human embryonic kidney HEK293
cells (ATCC, Manassas, VA, USA) as described elsewhere [39]. The GFP expressing virus was
titrated on Raji cells (ATCC, Manassas, VA, USA) in serial dilution and the GFP-expressing
cells were analyzed by flow cytometry 2 days later to calculate Raji-infectious units (RIU).
Mice with reconstituted human immune system components and infection
with EBV
NOD-scid γcnull (NSG) mice and HLA-A2 transgenic NSG were obtained from the Jackson
Laboratories and maintained under specific pathogen-free conditions. Newborn mice (1–5
days old) were irradiated with 1 Gy using a Cs or x-ray source and after 5 to 7 hours reconsti-
tuted intrahepatically with 1–3 x 105 CD34+ human hematopoietic progenitor cells (HPCs)
purified from human fetal liver (HFL) tissue obtained from Advanced Bioscience Resources.
Preparation of HFL tissue and isolation of human CD34+ cells were performed as described
previously [18, 24]. Human immune component reconstitution levels were checked 10–12
weeks later and again just before the start of the experiments by flow cytometric immune phe-
notyping of PBMCs as previously described [40]. Mice were infected intraperitoneally with
1 × 105 RIU of EBV wt, 3AKO or 3CKO or with 1 x 106 RIU of EBV 3AKO or 3CKO and fol-
lowed for 5 to 6 or 12 weeks respectively.
CD4+ cell depletion
CD4+ cells were depleted with 100 μg of monoclonal antibody against human CD4 (clone
OKT-4; Bio X Cell) via intraperitoneal inoculation for 3 consecutive days just prior to EBV
infection. To deplete CD4+ cells for the duration of 5 weeks, the same injection procedure was
repeated every 2 weeks.
Quantification of viral load
Splenic tissue was processed using a QIAamp DNA Tissue Kit (QIAGEN) and total DNA
from whole blood was extracted using the NucliSENS EasyMAG System (bioMe´rieux), both
according to the manufacturer’s recommendations. TaqMan (Applied Biosystems) real-time
EBV persistence without EBNA3A and 3C
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007039 April 30, 2018 13 / 19
PCR was used to quantify EBV DNA as previously described [41], with modified primers for
the BamH1 W fragment (50-CTTCTCAGTCCAGCGCGTTT-30 and 50-CAGTGGTCCCCCT
CCCTAGA-30) and a fluorogenic probe (50-FAM CGTAAGCCAGACAGCAGCCAATTGT
CAG-TAMRA-30). All PCRs were run on an ABI Prism 7700 Sequence Detector (Applied Bio-
systems), and samples were analyzed in duplicates. Samples below the lower limit of quantifi-
cation (LLOQ) of 67 EBV DNA copies were considered negative for EBV DNA. EBV wt
infected mice without any sign of EBV infection were excluded from the analysis.
Flow cytometry
All fluorescently labeled antibodies were purchased from BD Biosciences, BioLegend and Invi-
trogen (Thermo Fisher Scientific) (S1 Table). Lysis of erythrocytes in whole blood was done
with NH4Cl. Spleens were mechanically disrupted and filtered through a 70 μm cell strainer
before separation of mononuclear cells on Ficoll-Paque gradients. Cell suspensions were
stained with antibodies for 30 min on ice, washed, and analyzed on FACSCanto or LSR For-
tessa cytometers (BD Biosciences). Analysis of flow cytometric data was performed with
FlowJo (Tree Star). The absolute numbers of leukocytes in each category were computed from
the white blood cell count measured with a Beckman Coulter AcT diff Analyzer. Early apopto-
tic cells were assessed by incubating cells with AF647 annexin V (BioLegend) and 7AAD (Bio-
Legend) diluted in annexin binding buffer for 15 min at room temperature in the dark, 400 μl
binding buffer was added and the staining was directly analyzed on FACSCanto.
Histology, immunohistochemistry and immunofluorescence
Tissue was fixed in 10% saline buffered formalin and paraffin embedded. For immunohis-
tochemistry and immunofluorescence, 3 μm sections were processed on a Leica BOND-MAX
or Bond-III automated immunohistochemistry system. Stainings were performed with mono-
clonal mouse anti-EBNA2 (clone PE2, Abcam), mouse anti-LMP1 (clone CS.1-4, Novocastra),
mouse anti-BZLF1 (clone BZ1, Santa Cruz), mouse anti-CD138 (B-A38, Sigma-Aldrich), rat
anti-EBNA1 (clone 1H4, kind gift from Dr. Kremmer, Munich, Germany), rabbit anti-Ki67
(clone SP6, Cell Marque), rabbit anti-p16INK4a (clone EPR1473, Abcam), rabbit anti-CD3
(clone SP7, Diagnostic Biosystem), mouse anti-CD20 (clone L26, Dako) and rabbit anti-CD20
(Clone SP32, Cell Marque Lifescreen Ltd.). For immunofluorescence, the AF488 donkey anti-
rabbit IgG (Jackson ImmunoResearch), Cy3 donkey anti-mouse IgG (Jackson ImmunoRe-
search), DyLight549 horse anti-mouse IgG (Vectrolabs) and DAPI (Sigma) were used. In situ
hybridization (ISH) for EBV-encoded RNAs (EBER-ISH) was done as described previously,
employing diaminobenzidine (DAB) chromogen (Zytomed Systems, Berlin, Germany) as sub-
strate [42]. Quantification of BZLF1, EBER and EBER plus CD20 was performed as described
previously for quantitative evaluation of labeled cells [43]. The number of labeled cells was
determined per 1mm2 using the image analysis software HISTO (Biomas). EBNA2, LMP1 and
CD138 stainings, EBER ISH as well as EBNA2 plus CD3, EBNA2 plus CD20, EBNA2 plus
Ki67 and EBNA2 plus p16INK4a co-stainings were analyzed with a Vectra3 automated quantita-
tive pathology imaging system (PerkinElmer) using Vectra and InForm software analysis
(PerkinElmer). Snapshots were taken using a scanning protocol created with InForm tissue
segmentation to recognize the tissue. Briefly, the stained slides were loaded onto the Vectra
slide scanner, 1 to 10 images with 20 × objective lens (0.5 micron/pixel) were taken with a
CCD using the scanning protocol. Images taken were used to set up an algorithm in InForm to
recognize and count EBNA2, LMP1 or CD138 positive cells, respectively. Signal cross-talk was
eliminated using one chromogen only (DAB, hematoxylin or fast red) control stains. If the
algorithm was >90% confident that the signal was positive, the cells were counted and the
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number of positive cells per 1mm2 was determined. InForm was also used to set up an algo-
rithm to calculate the percentage of EBNA2 plus Ki67, EBNA2 plus CD20 and EBNA2 plus
CD3 double positive cells of all EBNA2 positive cells. The percentage of EBNA2 and p16INK4a
double positive cells of all EBNA2 positive cells was quantified by an independent observer.
B cell isolation from infected mice or human leucocyte concentrates
Human B cells were isolated from spleen suspensions of infected mice or from human leuco-
cyte concentrates (blood bank Zurich) using CD19 microbeads (Miltenyi Biotec) according to
the manufacturer’s recommendations.
In vitro infection of human B cells with wt, 3AKO or 3CKO EBV
106 magnetically sorted human B cells from human leukocyte concentrates were infected with
wt, 3AKO or 3CKO EBV with the addition of irradiated (140Gy) 3T3 fibroblast expressing
CD40L or not [29]. Irradiated fibroblasts were replaced weekly. The cells were maintained in
RPMI 1640 medium (Gibco, Thermo Fisher Scientific) with 10% FCS, streptomycin and peni-
cillin. Analysis of living cells was done using flow cytometry 14 and 21 days p.i..
qPCR for viral gene expression
RNA was isolated using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s rec-
ommendations either of the magnetically enriched CD19+ fraction of infected mice or infected
buffy coats. To remove contaminating genomic DNA, a 15min on-column DNAse treatment
was included during the RNA isolation (RNAse-Free DNAse Set, Qiagen). Purified RNA was
reverse transcribed using GoScript Reverse Transcriptase (Promega) for 1h at 42˚C according
to the recommendations of the manufacturer using a primer mix combining previously
described gene-specific RT primers [44] at concentrations of 10μM each. cDNA was used to
amplify EBNA2, LMP1, LMP2A, BZLF1 and GAPDH using previously published primers with
5’FAM/3’TAMRA [44], equal RNA input and Taqman universal PCR reagents (Applied Bio-
systems). qPCR was performed in triplicates on a C1000 Touch CFX384 Real-Time platform
(Bio-Rad, Hercules, CA, USA) as described elsewhere [45]. Cq values were determined with
the CFX-manager software (Biorad) and relative mRNA levels were normalized to the refer-
ence gene GAPDH. The detection limits of the RT-qPCR assays was calculated with the back-
ground Cq value and the highest GAPDH expression found in mouse samples of the used
experiments.
Statistical analysis
Statistical analysis and graph preparation was performed with Prism software (GraphPad).
Two-tailed Mann-Whitney U, unpaired two-tailed t-test with Welch’s correction, two-way
ANOVA tests with Bonferroni correction, paired t-test or Fisher’s exact test for actual numbers
were used. A p value of< 0.05 was considered statistically significant.
Ethics statement
All animal protocols were conducted according to the Swiss Animal Welfare Act, Tierschutz-
gesetz (TSchG) and approved by the veterinary office of the canton of Zurich, Switzerland
(protocols 148/2011, 209/2014 and 159/17). All studies involving human samples were
reviewed and approved by the cantonal ethics committee of Zurich, Switzerland (protocol
KEK-StV-Nr.19/08). The used human samples were anonymized.
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Supporting information
S1 Fig. EBV is mainly detected in B cells upon infection with 3AKO, 3CKO or wt viruses.
Staining for (A, B) EBNA2 and CD20 or (A, B) EBNA2 and CD3 of splenic sections of huNSG
mice infected with either (A) 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. or (B) 106 RIU of
3AKO or 3CKO 6 weeks p.i.. (C) Frequency of EBNA2+ cells with or without CD20 or CD3
expression in mice infected with either 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. or 106 RIU
of 3AKO or 3CKO. (D) EBER ISH and CD20 staining of splenic section of huNSG mice
infected with either 105 RIU of 3AKO or 3CKO 12 weeks p.i..
(TIF)
S2 Fig. EBNA3A or EBNA3C deficient EBV infections show a trend toward CD8+ T cell
expansion in peripheral blood. The change between the beginning and the end of the experi-
ment (Δend-start) in the number of (A) blood CD8+ T cells / ml and (B) blood CD4+ T cells /
ml of huNSG mice infected with either 105 RIU of wt, 3AKO or 3CKO 5 weeks p.i. (n = 14-17/
group) or 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 7-13/group) or non-infected control
(mock) huNSG mice as determined by flow cytometry and white blood cell counting with a
hemocytometer (A, B) Pooled data from 4 low and 2 high infectious dose experiments with
the mean ± SEM. P< 0.05, P< 0.01, P < 0.001, by Mann-Whitney U test.
(TIF)
S3 Fig. EBNA3A or EBNA3C deficient EBV infection causes T cell activation. The fre-
quency of HLA-DR+ CD8+ (A, C) blood and splenic (B, D) T cells or HLA-DR+ CD4+ (E, G)
blood and splenic (F, H) T cells of huNSG mice infected with either 105 RIU of wt, 3AKO or
3CKO 5 weeks p.i. (n = 14-21/group) or 106 RIU of 3AKO or 3CKO 6 weeks p.i. (n = 7-13/
group) or non-infected control (mock) huNSG mice was determined by flow cytometry.
(A-H) Pooled data from 4 low and 2 high infectious dose experiments with mean ± SEM.
P < 0.05, P< 0.01, P< 0.001, Mann-Whitney U test.
(TIF)
S4 Fig. EBNA3A and EBNA3C deficient EBV infected mice show reduced lytic replication.
(A) Representative immunohistochemistry staining for CD138 (original magnification, 200x)
and the (B) quantification of CD138+ cells/mm2 in splenic sections from huNSG mice infected
with 106 RIU of 3AKO or 3CKO at 6 weeks p.i. and from non-infected control (mock) huNSG
mice. Pooled data from 2 experiments represented with the mean ± SEM, Mann-Whitney U
test. (C) Representative immunohistochemistry staining for BZLF1 (original magnification,
400x) in splenic sections of huNSG mice infected with 106 RIU of 3AKO or 3CKO 6 weeks p.i.
and non-infected control (mock) huNSG mice.
(TIF)
S5 Fig. EBNA3C deficient EBV shows reduced lytic replication in vitro. Relative mRNA
expression of BZLF1 normalized to GAPDH as determined by RT-qPCR in purified human
CD19+ B cells infected with wt, 3AKO or 3CKO with or without irradiated fibroblasts (FB)
either expressing CD40L or not 3 weeks p.i. (n = 6–13). Pooled data from 3 experiments repre-
sented with the mean ± SEM, P < 0.05, P< 0.01, P< 0.001, Mann-Whitney U test.
(TIF)
S6 Fig. Elevated EBV loads in 3AKO infected mice upon CD4+ T cell depletion. (A) Splenic
endpoint viral DNA load and (B) viral DNA load per gram lymph node tissue determined by
qPCR of huNSG mice inoculated with a CD4 specific antibody and infected with 105 RIU of
3AKO or 3CKO for 5 weeks (n = 4-6/group). Values for mice in which no viral DNA was
detected are plotted on the X-axis. (C) Blood DNA viral load over time determined by qPCR
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of huNSG mice infected with 105 RIU of 3AKO or 3CKO 5 weeks p.i. (n = 4-6/group). Hori-
zontal dashed line indicates the viral load of 3 times the lower limit of quantification (LLOQ).
Horizontal dotted line indicates the LLOQ. (A-B) Data from 1 experiment is displayed
with geometric mean for splenic and lymph node viral load and SEM for blood viral load,
P < 0.05, P< 0.01, P< 0.001, two-way ANOVA with Bonferroni correction for blood
viral load and Mann-Whitney U test for splenic and lymph node viral load.
(TIF)
S1 Table. Overview of fluorescently labeled antibodies used in this study for flow cytome-
try.
(DOCX)
Author Contributions
Conceptualization: Anita Murer, Martin Allday, Obinna Chijioke, Christian Mu¨nz.
Data curation: Anita Murer, Donal McHugh, Nicole Caduff, Mario Barros, Andrea Zbinden,
Riccarda Capaul.
Formal analysis: Anita Murer, Mario Barros, Obinna Chijioke, Christian Mu¨nz.
Funding acquisition: Gerald Niedobitek, Christian Mu¨nz.
Investigation: Anita Murer, Donal McHugh, Nicole Caduff, Mario Barros.
Methodology: Anita Murer, Nicole Caduff, Jens Kalchschmidt, Mario Barros, Andrea Zbin-
den, Riccarda Capaul.
Project administration: Christian Mu¨nz.
Resources: Jens Kalchschmidt, Andrea Zbinden, Riccarda Capaul.
Supervision: Gerald Niedobitek, Martin Allday, Obinna Chijioke, Christian Mu¨nz.
Writing – original draft: Anita Murer, Obinna Chijioke, Christian Mu¨nz.
Writing – review & editing: Donal McHugh, Nicole Caduff, Jens Kalchschmidt, Mario Barros,
Andrea Zbinden, Riccarda Capaul, Gerald Niedobitek, Martin Allday.
References
1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma.
Lancet. 1964; 1:702–3. PMID: 14107961
2. Epstein MA, Henle G, Achong BG, Barr YM. Morphological and biological studies on a virus in cultured
lymphoblasts from Burkitt’s lymphoma. J Exp Med. 1964; 121:761–70.
3. Nilsson K, Klein G, Henle W, Henle G. The establishment of lymphoblastoid lines from adult and fetal
human lymphoid tissue and its dependence on EBV. Int J Cancer. 1971; 8(3):443–50. PMID: 4332899
4. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol. 2014; 9:349–
72. https://doi.org/10.1146/annurev-pathol-012513-104656 PMID: 24111911
5. Babcock JG, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent
genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 2000; 13
(4):497–506. PMID: 11070168
6. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration
of the Burkitt’s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in
vivo. Proc Natl Acad Sci U S A. 2004; 101(1):239–44. https://doi.org/10.1073/pnas.2237267100 PMID:
14688409
7. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo.
Immunity. 1998; 9(3):395–404. PMID: 9768759
EBV persistence without EBNA3A and 3C
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007039 April 30, 2018 17 / 19
8. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle
of Epstein-Barr virus in vivo. J Virol. 2005; 79(2):1296–307. https://doi.org/10.1128/JVI.79.2.1296-
1307.2005 PMID: 15613356
9. Altmann M, Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the
immediate inhibition of apoptosis. PLoS Biol. 2005; 3(12):e404. https://doi.org/10.1371/journal.pbio.
0030404 PMID: 16277553
10. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE, et al. An ATM/Chk2-mediated DNA
damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human
B cells. Cell Host Microbe. 2010; 8(6):510–22. https://doi.org/10.1016/j.chom.2010.11.004 PMID:
21147465
11. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ. BIM promoter directly targeted by
EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res. 2012; 40(15):7233–46. https://
doi.org/10.1093/nar/gks391 PMID: 22584624
12. Skalska L, White RE, Parker GA, Turro E, Sinclair AJ, Paschos K, et al. Induction of p16(INK4a) is the
major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblas-
toid cell lines. PLoS Pathog. 2013; 9(2):e1003187. https://doi.org/10.1371/journal.ppat.1003187 PMID:
23436997
13. Allday MJ, Bazot Q, White RE. The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that
Are Central to the Biology of EBV in B Cells. Curr Top Microbiol Immunol. 2015; 391:61–117. https://
doi.org/10.1007/978-3-319-22834-1_3 PMID: 26428372
14. Tomkinson B, Robertson E, Yalamanchili R, Longnecker R, Kieff E. Epstein-Barr virus recombinants
from overlapping cosmid fragments. J Virol. 1993; 67(12):7298–306. PMID: 8230453
15. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, Lang R, et al. Differential gene expression pat-
terns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog. 2009; 5(7):
e1000506. https://doi.org/10.1371/journal.ppat.1000506 PMID: 19578441
16. Price AM, Tourigny JP, Forte E, Salinas RE, Dave SS, Luftig MA. Analysis of Epstein-Barr virus-regu-
lated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent
membrane protein 1-mediated NF-kappaB activation. J Virol. 2012; 86(20):11096–106. https://doi.org/
10.1128/JVI.01069-12 PMID: 22855490
17. Wasil LR, Tomaszewski MJ, Hoji A, Rowe DT. The effect of Epstein-Barr virus Latent Membrane Pro-
tein 2 expression on the kinetics of early B cell infection. PLoS ONE. 2013; 8(1):e54010. https://doi.org/
10.1371/journal.pone.0054010 PMID: 23308294
18. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, et al. EBNA3B-deficient EBV
promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest.
2012; 122(4):1487–502. https://doi.org/10.1172/JCI58092 PMID: 22406538
19. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, et al. IL-21 imposes a type II EBV gene
expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc
Natl Acad Sci U S A. 2010; 107(2):872–7. https://doi.org/10.1073/pnas.0912920107 PMID: 20080768
20. Nagy N, Adori M, Rasul A, Heuts F, Salamon D, Ujvari D, et al. Soluble factors produced by activated
CD4+ T cells modulate EBV latency. Proc Natl Acad Sci U S A. 2012; 109(5):1512–7. https://doi.org/10.
1073/pnas.1120587109 PMID: 22307606
21. Mu¨nz C. Epstein Barr virus—a tumor virus that needs cytotoxic lymphocytes to persist asymptomati-
cally. Curr Opin Virol. 2016; 20:34–9. https://doi.org/10.1016/j.coviro.2016.08.010 PMID: 27591678
22. Gujer C, Chatterjee B, Landtwing V, Raykova A, McHugh D, Mu¨nz C. Animal models of Epstein Barr
virus infection. Curr Opin Virol. 2015; 13:6–10. https://doi.org/10.1016/j.coviro.2015.03.014 PMID:
25846986
23. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, et al. T cell-mediated
control of Epstein-Barr virus infection in humanized mice. J Infect Dis. 2009; 200(10):1611–5. https://
doi.org/10.1086/644644 PMID: 19832115
24. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J, et al. Priming of protective T cell responses
against virus-induced tumors in mice with human immune system components. J Exp Med. 2009; 206
(6):1423–34. https://doi.org/10.1084/jem.20081720 PMID: 19487422.
25. Takada K, Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus
genomes. J Virol. 1989; 63(1):445–9. PMID: 2462063
26. Grogan E, Jenson H, Countryman J, Heston L, Gradoville L, Miller G. Transfection of a rearranged viral
DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lym-
phoid cells. Proc Natl Acad Sci U S A. 1987; 84(5):1332–6. PMID: 3029778
27. Gan YJ, Sullivan JL, Sixbey JW. Detection of cell-free Epstein-Barr virus DNA in serum during acute
infectious mononucleosis. J Infect Dis. 1994; 170(2):436–9. PMID: 8035032
EBV persistence without EBNA3A and 3C
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007039 April 30, 2018 18 / 19
28. Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, et al. LMP1-deficient Epstein-Barr
virus mutant requires T cells for lymphomagenesis. J Clin Invest. 2015; 125(1):304–15. https://doi.org/
10.1172/JCI76357 PMID: 25485679
29. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells:
an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific
T cells for adoptive immunotherapy. J Clin Invest. 1997; 100(11):2757–65. https://doi.org/10.1172/
JCI119822 PMID: 9389740
30. Allday MJ, Crawford DH, Thomas JA. Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of
the EBV latent membrane protein and an activated phenotype in Raji cells. J Gen Virol. 1993; 74 (Pt
3):361–9.
31. Jimenez-Ramirez C, Brooks AJ, Forshell LP, Yakimchuk K, Zhao B, Fulgham TZ, et al. Epstein-Barr
virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J
Virol. 2006; 80(22):11200–8. https://doi.org/10.1128/JVI.00897-06 PMID: 16956945
32. Zhao B, Sample CE. Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 pro-
moter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-
1/Spi-B binding site. J Virol. 2000; 74(11):5151–60. PMID: 10799590
33. Lin J, Johannsen E, Robertson E, Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression
domain mediates coactivation of the LMP1 promoter with EBNA-2. J Virol. 2002; 76(1):232–42. https://
doi.org/10.1128/JVI.76.1.232-242.2002 PMID: 11739688
34. Kieser A, Sterz KR. The Latent Membrane Protein 1 (LMP1). Curr Top Microbiol Immunol. 2015;
391:119–49. https://doi.org/10.1007/978-3-319-22834-1_4 PMID: 26428373
35. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with
Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting,
latently infected cells. J Virol. 2004; 78(10):5194–204. https://doi.org/10.1128/JVI.78.10.5194-5204.
2004 PMID: 15113901
36. Kurth J, Spieker T, Wustrow J, Strickler GJ, Hansmann LM, Rajewsky K, et al. EBV-infected B cells in
infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing
latency. Immunity. 2000; 13(4):485–95. PMID: 11070167
37. Meixlsperger S, Leung CS, Ramer PC, Pack M, Vanoaica LD, Breton G, et al. CD141+ dendritic cells
produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in
humanized mice. Blood. 2013; 121(25):5034–44. https://doi.org/10.1182/blood-2012-12-473413 PMID:
23482932
38. Salguero G, Daenthanasanmak A, Mu¨nz C, Raykova A, Guzman CA, Riese P, et al. Dendritic cell-medi-
ated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplanta-
tion. J Immunol. 2014; 192(10):4636–47. https://doi.org/10.4049/jimmunol.1302887 PMID: 24740501
39. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein-Barr virus (EBV) oncoproteins
cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis
of Burkitt’s lymphoma. Oncogene. 2008; 27(4):421–33. https://doi.org/10.1038/sj.onc.1210668 PMID:
17653091
40. Antsiferova O, Mu¨ller A, Ra¨mer P, Chijioke O, Chatterjee B, Raykova A, et al. Adoptive transfer of EBV
specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog.
2014; 10(8):e1004333. https://doi.org/10.1371/journal.ppat.1004333 PMID: 25165855
41. Berger C, Day P, Meier G, Zingg W, Bossart W, Nadal D. Dynamics of Epstein-Barr virus DNA levels in
serum during EBV-associated disease. J Med Virol. 2001; 64(4):505–12. PMID: 11468736
42. Meyer M, Hols AK, Liersch B, Leistner R, Gellert K, Schalke B, et al. Lack of evidence for Epstein-Barr
virus infection in myasthenia gravis thymus. Ann Neurol. 2011; 70(3):515–8. https://doi.org/10.1002/
ana.22522 PMID: 21905083
43. Barros MH, Vera-Lozada G, Soares FA, Niedobitek G, Hassan R. Tumor microenvironment composi-
tion in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection. Int J
Cancer. 2012; 131(5):1142–52. https://doi.org/10.1002/ijc.27314 PMID: 22025264
44. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, et al. Analysis of Epstein-Barr virus latent
gene expression in endemic Burkitt’s lymphoma and nasopharyngeal carcinoma tumour cells by using
quantitative real-time PCR assays. J Gen Virol. 2006; 87(Pt 10):2885–90. https://doi.org/10.1099/vir.0.
81906-0 PMID: 16963746
45. McHugh D, Caduff N, Barros MHM, Ra¨mer P, Raykova A, Murer A, et al. Persistent KSHV infection
increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host &
Microbe. 2017; 22(1):61–73.
EBV persistence without EBNA3A and 3C
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007039 April 30, 2018 19 / 19
